drugset / Trial / NCT07158151

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

NCT07158151 ↗

Phase 2 Completed 168 enrolled Reistone Biopharma Company Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis

Timeline

Start
2025-09-25
Primary completion
2026-04-10
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator RSS0393 Unknown 0.01 % —
Comparator RSS0393 Unknown 0.03 % —
Comparator RSS0393 Unknown 0.05 % —

Indications